Evidence map›Paper›PMID 37744849›Full record

ArticleACS omega2023

Transcriptomics-Guided In Silico Drug Repurposing: Identifying New Candidates with Dual-Stage Antiplasmodial Activity.

Joyce V B Borba, Beatriz Rosa de Azevedo, Larissa A Ferreira, Aline Rimoldi, Luís C Salazar Alvarez, Juliana Calit, Daniel Y Bargieri, Fabio T M Costa, Carolina Horta Andrade

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Joyce V B BorbaLaboratory for Molecular Modeling and Drug Design (LabMol), Faculdade de Farmacia, Universidade Federal de Goias, 74605-170 Goiânia, Goiás, Brazil.ORCID https://orcid.org/0000-0002-2663-5173
Beatriz Rosa de AzevedoLaboratory for Molecular Modeling and Drug Design (LabMol), Faculdade de Farmacia, Universidade Federal de Goias, 74605-170 Goiânia, Goiás, Brazil.
Larissa A FerreiraLaboratory of Tropical Diseases-Prof. Dr. Luiz Jacintho da Silva, Department of Genetics Evolution, Microbiology and Immunology, University of Campinas, 13083-970 Campinas, São Paulo, Brazil.
Aline RimoldiLaboratory of Tropical Diseases-Prof. Dr. Luiz Jacintho da Silva, Department of Genetics Evolution, Microbiology and Immunology, University of Campinas, 13083-970 Campinas, São Paulo, Brazil.
Luís C Salazar AlvarezLaboratory of Tropical Diseases-Prof. Dr. Luiz Jacintho da Silva, Department of Genetics Evolution, Microbiology and Immunology, University of Campinas, 13083-970 Campinas, São Paulo, Brazil.
Juliana CalitDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, 05508-000 São Paulo, São Paulo, Brazil.
Daniel Y BargieriDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, 05508-000 São Paulo, São Paulo, Brazil.
Fabio T M CostaLaboratory of Tropical Diseases-Prof. Dr. Luiz Jacintho da Silva, Department of Genetics Evolution, Microbiology and Immunology, University of Campinas, 13083-970 Campinas, São Paulo, Brazil.
Carolina Horta AndradeLaboratory for Molecular Modeling and Drug Design (LabMol), Faculdade de Farmacia, Universidade Federal de Goias, 74605-170 Goiânia, Goiás, Brazil.ORCID https://orcid.org/0000-0003-0101-1492

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In tropical and subtropical areas, malaria stands as a profound public health challenge, causing an estimated 247 million cases worldwide annually. Given the absence of a viable vaccine, the timely and effective treatment of malaria remains a critical priority. However, the growing resistance of parasites to currently utilized drugs underscores the critical need for the identification of new antimalarial therapies. Here, we aimed to identify potential new drug candidates against

Identifiers

PMID37744849
PMCPMC10515587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.